MPP at ICASA 2021: Paving the way to access to long-acting technologies
Paving the way to access to long-acting technologies
On 9 December, the Medicines Patent Pool held an online satellite symposium at ICASA entitled “Paving the way to access to long-acting technologies”. With the recent signing of the first MPP long-acting technologies voluntary licence, what should we consider in order to enhance access to long-acting therapeutics for HIV prevention and treatment, and why is it critical to anticipate potential access hurdles as early as possible?
Opening remarks were made by Lobna Gayeeb from MPP. She announced a licence agreement between MPP and the University of Washington for an investigational long-acting injectable drug combination candidate for HIV. Cherise Scott from Unitaid announced the launch of a landscape report on novel technologies for the prevention of HIV, STIs, and unwanted pregnancy.
A panel discussion followed with questions to:
- Prof. Quarraisha Abdool Karim, CAPRISA
- Dr. N Kumarasamy, Clinton Health Access Initiative
- Yves Kugbe, Long-Acting Technologies Community Advisory Board
- Siobhan Crowley, The Global Fund
Sandra Nobre from MPP made concluding remarks.
